Free medical samples are a simple case that clearly shows how pharmaceutical traceability has one global baseline… but each hub applies it with its own logic.
- In Tatmeen (UAE) → free samples (conventional / biological) still need to be reported.
- In RSD-SFDA (Saudi Arabia)→ commercial samples are exempt, but if SFDA will test them at port they must be deactivated in the system.
- In Egypt-EDA → certain free medical / research samples fall outside the standard commercial distribution traceability scope.
So the principle stays the same,but the workflow is never copy-past.
each hub defines the operational way based on local risk appetite + market maturity + regulator priorities.
That’s why track & trace professionals can’t just say “we already implemented this in Country A” … each market needs its own configuration thinking.